Wall Street can wait: Why one U.S. biotech firm is listing in Hong Kong first
Sign in to use saved chat.
This room keeps conversation history for your account, so sending here needs a login. The box on the front page answers without one.
About this room
Axiom Biosciences, a U.S. biotech firm, plans to list in Hong Kong in 2027 before a secondary U.S. listing in 2029, citing access to sophisticated biotech investors and proximity to Asian partners. The company’s CEO noted that Hong Kong’s stricter listing standards reflect a mature biotech ecosystem, and that the city’s biotech index has outperformed U.S. indexes since early 2025. The move highlights a growing trend of biotech firms turning to Hong Kong amid a tougher fundraising environment and expanding investor base.
View original →